Abstract library

157 results for "anti-tumor drug".
#2874 Role of FOXM1 in Aggressive Pancreatic / Pulmonary Neuroendocrine Carcinomas and Anti-Tumor Effect of the FOXM1 Inhibitor Thiostrepton
Introduction: DNA-targeting agents are the main treatment of aggressive pulmonary and pancreatic neuroendocrine carcinomas (NEC). FOXM1 is a transcription factor controlling cell proliferation and DNA repair pathways, playing therefore an important role in tumor progression and chemoresistance.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr Jerome Cros
#2898 Novel Preclinical Models of Small Bowel Neuroendocrine Tumors for Drug Screening
Introduction: The incidence of neuroendocrine tumors (NETs) from the small bowel (SBNETs) has increased markedly over the past several decades. Many patients with these tumors present with metastatic disease, and research into new treatment options for these tumors have been hindered by the limited number of patient-derived SBNET cell lines and in vivo models available for drug testing.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Assistant Profes Po Hien Ear
Authors: Ear P H, Tran C, Li G, Kaemmer C, ...
#2884 An Infectious Diseases Specialist NET Patient Looks at Management of NETs
Introduction: Medical specialties may develop practices minimally influenced by other specialties.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Doctor George Schmid
Authors: Schmid G, ...
#220 The Global mTOR Inhibitor Torin1 is More Effective than the mTORC1 Inhibitor, Everolimus, Alone or in Combination with Histone Deacetylases Inhibitors, in Suppressing Neuroendocrine Tumors Cell Proliferation
Introduction: Torin1, a new mTOR inhibitor that globally inhibits both mTORC1 and mTORC2, seems to impair cell growth and proliferation to a greater degree than rapamycin; its effects in NET cells are unknown.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr. Simona Grozinsky-Glasberg
#643 Phase II Study of Pazopanib Monotherapy in Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Treatment options for patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP NETs) are still limited. The anti-angiogenic approach in metastatic pancreatic NETs has shown promising results.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - Others
Presenting Author: Professor Young Suk Park
Authors: Park Y S, Ahn H K, Lee J, Choi J Y, ...
Keywords: Pazopanib, GEP-NETs
#1238 Use of Everolimus in a Patient with Metastatic Bronchial Carcinoid Receiving Hemodialysis.
Introduction: Renal impairment may alter the normal pharmacokinetic and pharmacodynamic behavior of chemotherapy drugs, thus increasing the risk of side effects. Everolimus was reported to have anti-tumor activity in bronchial neuroendocrine tumors (NET). Safety and toxicity profile of everolimus has been provided in hemodialyzed patients with renal cell carcinoma. Only a report describes the effect of everolimus in a patient with metastatic ileac carcinoid in hemodialysis.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Clinical cases/reports
Presenting Author: MD Maria Pia Brizzi
#1637 The Effect of the Autophagy Inhibitor Chloroquine (CQ), Alone or in Combination with mTOR Inhibitors, on Neuroendocrine Tumor (NET) Growth and Metastatic Spread in Mouse Models
Introduction: mTOR inhibitors (mTORi) such as RAD001 demonstrated promising anti-cancer effect in NETs. Autophagy, a cell survival mechanism, is activated by mTORi. We have recently shown in the human NET cell line BON1 that autophagy is essential for cell survival. Treatment with CQ alone or together with mTORi robustly inhibited cell proliferation and survival, suggesting that treatment with CQ may potentiate the anti-tumorigenic effects of mTORi.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: MD Simona Grozinsky-Glasberg
Keywords: autophagy, mTORi, NET
#2142 Preliminary Safety and Efficacy of Rovalpituzumab Tesirine in Patients with Delta-Like Protein 3-Expressing Advanced Solid Tumors
Introduction: Rovalpituzumab tesirine (Rova-T™) is an antibody-drug conjugate targeting delta-like protein 3 (DLL3), an atypical Notch receptor family ligand expressed in high-grade neuroendocrine carcinomas (NECs).
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Endocrine malignancies (MTC, pheochromocytoma) - diagnosis and therapy
Presenting Author: PhD Jennifer Wietzke
#2742 Anti-Tumor Effects of Semaphorin 4D Blockade Unravel a Novel Pro-Invasive Mechanism of Vascular Targeting Agents
Introduction: One of the main consequences of inhibition of neovessel growth produced by angiogenesis inhibitors is increased intratumor hypoxia. Growing evidence indicates that tumor cells escape from this hypoxic environment to better nourished locations, presenting hypoxia as a positive stimulus for invasion. Particularly, anti-VEGF/R therapies produce hypoxia-induced invasion and metastasis in a spontaneous mouse model of pancreatic neuroendocrine cancer, RIP1-Tag2.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: PhD Oriol Casanovas
#2905 DNA Methyltransferase Inhibitor Hydralazine Induces Upregulation of Somatostatin Type 2 Receptors in Human Neuroendocrine Tumor Cells
Introduction: Epidrugs like DNA methyltransferase inhibitors (DNMTi) can increase somatostatin receptor type 2 (SST2) expression in neuroendocrine tumor (NET) cells in vitro and in vivo. This effect could be used for NET patients with low SST2 expression who are currently ineligible for somatostatin analogue (SSA) treatment. However, the DNMTi known to stimulate SST2 have either a high toxicity profile or are not yet approved.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Julie Refardt